Charles Schwab Investment Management Inc Anavex Life Sciences Corp. Transaction History

Charles Schwab Investment Management Inc

$515 Billion
Q3 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 665,976 shares of AVXL stock, worth $6.13 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

665,976

Previous 651,084 2.29%

Holding current value

$6.13 Million

Previous $2.75 Million 37.68%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$4.11 - $7.04 $61,206 - $104,839	14,892 Added 2.29%	665,976 $3.78 Million
Q2 2024 Aug 12, 2024	BUY	$3.39 - $5.02 $71,247 - $105,505	21,017 Added 3.34%	651,084 $2.75 Million
Q1 2024 May 08, 2024	BUY	$4.55 - $6.75 $35,294 - $52,359	7,757 Added 1.25%	630,067 $3.21 Million
Q4 2023 Feb 06, 2024	BUY	$5.04 - $9.95 $88,194 - $174,115	17,499 Added 2.89%	622,310 $5.79 Million
Q3 2023 Nov 08, 2023	BUY	$6.55 - $9.37 $154,245 - $220,654	23,549 Added 4.05%	604,811 $3.96 Million
Q2 2023 Aug 09, 2023	BUY	$7.66 - $9.5 $162,537 - $201,580	21,219 Added 3.79%	581,262 $4.73 Million
Q1 2023 May 11, 2023	SELL	$8.32 - $11.75 $46,966 - $66,328	-5,645 Reduced 1.0%	560,043 $4.8 Million
Q4 2022 Feb 13, 2023	BUY	$7.65 - $14.43 $174,641 - $329,422	22,829 Added 4.21%	565,688 $5.24 Million
Q3 2022 Nov 14, 2022	BUY	$8.9 - $12.86 $170,363 - $246,166	19,142 Added 3.66%	542,859 $5.6 Million
Q2 2022 Aug 15, 2022	SELL	$7.31 - $12.84 $50,943 - $89,481	-6,969 Reduced 1.31%	523,717 $5.24 Million
Q1 2022 May 13, 2022	BUY	$9.74 - $17.69 $144,600 - $262,625	14,846 Added 2.88%	530,686 $6.53 Million
Q4 2021 Feb 11, 2022	BUY	$16.88 - $23.31 $280,781 - $387,738	16,634 Added 3.33%	515,840 $8.95 Million
Q3 2021 Nov 16, 2021	BUY	$16.82 - $25.75 $5.72 Million - $8.76 Million	340,353 Added 214.26%	499,206 $8.96 Million
Q2 2021 Aug 16, 2021	BUY	$10.16 - $28.86 $103,774 - $294,776	10,214 Added 6.87%	158,853 $3.63 Million
Q1 2021 May 17, 2021	BUY	$5.17 - $16.13 $73,357 - $228,868	14,189 Added 10.55%	148,639 $2.22 Million
Q4 2020 Feb 16, 2021	BUY	$4.01 - $7.58 $33,146 - $62,656	8,266 Added 6.55%	134,450 $727,000
Q2 2020 Aug 14, 2020	BUY	$2.62 - $5.2 $14,795 - $29,364	5,647 Added 4.68%	126,184 $621,000
Q1 2020 May 15, 2020	BUY	$2.38 - $5.81 $34,072 - $83,175	14,316 Added 13.48%	120,537 $380,000
Q3 2019 Nov 08, 2019	BUY	$2.22 - $3.9 $2,313 - $4,063	1,042 Added 0.99%	106,221 $336,000
Q2 2019 Aug 09, 2019	BUY	$2.75 - $3.7 $245,588 - $330,428	89,305 Added 562.59%	105,179 $355,000
Q1 2019 May 14, 2019	BUY	$1.68 - $3.42 $26,668 - $54,289	15,874 New	15,874 $49,000
Q2 2018 Aug 08, 2018	SELL	$2.08 - $4.26 $158,496 - $324,612	-76,200 Closed	0 $0
Q1 2018 May 07, 2018	BUY	$2.32 - $3.44 $57,999 - $86,000	25,000 Added 48.83%	76,200 $211,000
Q3 2017 Nov 13, 2017	BUY	$3.42 - $4.87 $175,104 - $249,344	51,200	51,200 $212,000

Others Institutions Holding AVXL

# of Institutions

161

Shares Held

27.4M

Call Options Held

515K

Put Options Held

838K

View Full List

About ANAVEX LIFE SCIENCES CORP.

Ticker AVXL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,942,800
Market Cap $718M
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...

More about AVXL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account

Charles Schwab Investment Management Inc Anavex Life Sciences Corp. Transaction History